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Mutational analysis of the PTEN/MMAC1 gene
in primary oesophageal squamous cell carcinomas
Y C Hu, K Y Lam, J C O Tang, G Srivastava
Abstract
Aim—To investigate whether PTEN/
MMAC1 mutations play a role in the car-
cinogenesis of oesophageal squamous cell
carcinoma.
Methods—A panel of 33 primary oesopha-
geal squamous cell carcinoma tumour
samples and 20 corresponding morpho-
logically normal tissues was examined for
mutations in all nine exons of the PTEN/
MMAC1 gene by means of polymerase
chain reaction single strand conforma-
tional polymorphism analysis (PCR–
SSCP) and direct DNA sequencing
methods.
Results—Only one of 33 oesophageal
squamous cell carcinomas showed an
aberrant SSCP band. Further sequencing
analysis of this sample revealed an 802 −29
T → C substitution in intron 7. PTEN/
MMAC1 mutations were not found in the
mutational “hot spot” in exon 5, even after
direct sequencing of six oesophageal
squamous cell carcinoma samples and
three normal tissues. However, a deletion
of one nucleotide T at position 492 +8 in
intron 5 was seen in all samples.
Conclusion—These results suggest that
PTEN/MMAC1 mutations do not play a
major role in the carcinogenesis of
oesophageal squamous cell carcinoma.
(J Clin Pathol:Mol Pathol 1999;52:353–356)
Keywords: oesophageal carcinoma; mutation; PTEN/
MMAC1; polymerase chain reaction single strand con-
formational polymorphism analysis
A novel candidate tumour suppressor gene, the
PTEN/MMAC1 (phosphatase and tensin
homologue deleted on chromosome ten/
mutated in multiple advanced cancers 1) gene,
also known as TEP1 (transforming growth fac-
tor â regulated and epithelial cell enriched
phosphatase), located at the chromosome
10q23 region, has been isolated recently by
three independent research groups.1–3 The
PTEN/MMAC1 gene encodes a 403 amino
acid dual specific phosphatase and shows
sequence homology with the cytoskeletal pro-
teins (tensin and auxilin).1–4 Somatic mutations
of the PTEN/MMAC1 gene were initially
detected in a variety of human cancer cell lines
and primary tumours of brain, prostate, breast,
and kidney.1 2 Germline mutations of the
PTEN/MMAC1 gene have also been found in
patients with Cowden disease5 6 and Bannayan-
Zonana syndrome.5 7 Although subsequent
studies revealed PTEN/MMAC1 mutations in
a wide variety of tumour types, some studies
uncovered no PTEN/MMAC1 mutations in
other tumours,8–11 indicating that the PTEN/
MMAC1 gene might play a role in the tumori-
genesis of some cancers but not others.
Oesophageal squamous cell carcinoma is
one of the most common cancers worldwide,
with a particularly high frequency in Chinese
patients.12 Despite its prevalence, the exact
molecular pathogenesis of oesophageal
squamous cell carcinoma is still uncertain. To
date, mutational analysis of the PTEN/
MMAC1 gene in oesophageal squamous cell
carcinomas has not been reported. Therefore,
to determine whether PTEN/MMAC1 muta-
tions play a role in the pathogenesis of
oesophageal squamous cell carcinoma, we ana-
lysed 33 oesophageal squamous cell carcinoma
tumour samples and 20 corresponding normal
oesophageal tissues by polymerase chain reac-
tion single strand conformational polymor-
phism analysis (PCR–SSCP) and direct DNA
sequencing methods. Our data suggest that
PTEN/MMAC1mutations do not play a major
role in the carcinogenesis of oesophageal
squamous cell carcinoma.
Materials and methods
COLLECTION OF TISSUE AND PATHOLOGICAL DATA
Matched normal and tumour samples were
collected prospectively from 20 Chinese pa-
tients who underwent surgery for oesophageal
squamous cell carcinoma during 1997 at
Queen Mary Hospital, the University of Hong
Kong. Another 13 oesophageal squamous cell
carcinoma tumour samples were collected in
1997 from the First University Hospital, West
China University of Medical Sciences
(Chengdu, China). Altogether, there were 26
men and seven women. The patient ages
ranged from 46 to 82 years, with a mean age of
58 years. The tumours were found in the upper
(n = 4), middle (n = 21), and lower (n = 8)
third of the oesophagus. The median length of
the tumours was 5 cm (range, 1 to 19.5). The
histology of the carcinomas was reviewed
according to the criteria described previously.13
The squamous carcinomas were well diVeren-
tiated in five cases, moderately diVerentiated in
23, and poorly diVerentiated in five. The
tumours were staged according to the TNM
classification.14 Most tumours were stage III
(n = 19); of the remainder, one was stage I,
nine were stage II, and four were stage IV.
DNA EXTRACTION
Excised fresh tissues from the tumours and the
corresponding non-tumour samples were snap
frozen in liquid nitrogen after surgical resection
and stored at −70°C before DNA extraction.
Cryostat sections were prepared from these
fresh frozen tissues. They were checked micro-

















scopically to determine their suitability for
DNA analysis. The selection criterion for use
of the tumour block was the extent of tumour
present (surface area > 4 cm2 and > 70% of
the area occupied by the tumour). DNA was
then extracted from selected tissues according
to the method described previously.15
PCR–SSCP ANALYSIS
All samples were screened for mutations in all
nine exons of the PTEN/MMAC1 gene by
SSCP analysis. The nine exons were amplified
using the previously described intronic
primers.6 16 Table 1 lists the sequences of these
primers. Samples with alterations were ana-
lysed at least twice.
All the primers used in our study were com-
mercially synthesised by Integrated DNA
Technologies Inc (Coralville, Iowa, USA). The
PCR reaction mixture consisted of 1× PCR
buVer, 1.5 or 2 mM MgCl2, 0.25 µM primers,
200 µM dNTPs, 1 µCi of [á-32P]dCTP (Amer-
sham, Aylesbury, UK), 0.5 U Taq polymerase
(Life Technologies Inc, Gaithersburg, Mary-
land, USA), and 20 ng of genomic DNA in a
total 25 µl reaction volume. All exons were
amplified with the following PCR conditions:
pretreatment at 94°C for four minutes, 35
cycles of amplification, and a single 10 minute
final extension procedure. Each of these 35
cycles consisted of a denaturing step at 94°C
for one minute, an annealing step of one
minute (55°C for exon 1; 54°C for exons 2–5,
8, and 9; and 53°C for exons 6 and 7), and an
extension step at 72°C for one minute. The
PCR products were mixed with an equal
volume of SSCP dye mixture (98% forma-
mide, 20 mM EDTA, 0.05% bromphenol
blue, 0.05% xylene cyanol FF, and 20 mM
NaOH), heat denatured at 97°C for seven
minutes, and rapidly placed on ice water for
more than five minutes. A 5 µl aliquot of each
denatured mixture was loaded on to an 8%
polyacrylamide gel containing 10% formamide
and electrophoresed at 4–6 W for 16 hours at
room temperature with a cool air conditioner
blowing on it. The gel was lifted with Whatman
3MM paper (Whatman International Ltd,
Maidstone, Kent, UK) and dried at 80°C for
90 minutes. This was followed by autoradiog-
raphy with Fuji-RX films (Tokyo, Japan) at
−70°C for one to three days.
DNA SEQUENCING
The abnormally migrating bands were excised
from gels after autoradiography and suspended
in deionised water overnight. The samples were
then reamplified using the same conditions as
in SSCP analysis except omitting the
[á-32P]dCTP. The PCR products were sub-
jected to electrophoresis in 2% low melting
point agarose gel. The amplified band was cut
out and purified using the Wizard PCR prepa-
rations DNA purification system (Promega,
Madison,Wisconsin, USA). The purified PCR
products were sequenced on an ABI 377 DNA
automated sequencer using a dye terminator
cycle sequencing ready reaction kit (Perkin-
Elmer, Norwalk, Connecticut, USA). The
sequencing primers were the same as those
used for the PCR–SSCP procedure. The DNA
sequencing procedure was performed twice in
each case to confirm the findings.
In addition, six randomly chosen tumour
samples and three corresponding morphologi-
cally normal tissues with normal SSCP pat-
terns were used to sequence exon 5 and its
flanking regions after PCR product purifica-
tion. The sequencing primers were the same as
those used for the PCR–SSCP procedure.
Table 1 Primers used for mutation analysis of PTEN/MMAC1 gene
Exon Forward primer sequence (5'–3') Reverse primer sequence (5'–3') Ref
1 AGT CGC CTG TCA CCA TTT C ACT ACG GAC ATT TTC GCA TC 6
2 GTT TGA TTG CTG CAT ATT TCA G GGC TTA GAA ATC TTT TCT AAA TG 16
3 AAT GAC ATG ATT ACT ACT CTA TTA ATC GGT TTA GGA ATA CAA 16
4 CAT TAT AAA GAT TCA GGC AAT G GAC AGT AAG ATA CAG TCT ATC 16
5 ACC TGT TAA GTT TGT ATG CAA C TCC AGG AAG AGG AAA GGA AA 6
6 CAT AGC AAT TTA GTG AAA TAA CT GAT ATG GTT AAG AAA ACT GTT C 6
7 TGA CAG TTT GAC AGT TAA AGG GGA TAT TTC TCC CAA TGA AAG 6
8 CTC AGA TTG CCT TAT AAT AGT C TCA TGT TAC TGC TAC GTA AAC 6
9 AAG GCC TCT TAA AAG ATC ATG TTT TCA TGG TGT TTT ATC CCT C 6
Figure 1 (A) Single strand conformational polymorphism (SSCP) analysis of
PTEN/MMAC1 exon 8.The arrowhead shows an extra SSCP band in the tumour sample.
N,DNA from corresponding normal tissue; T, tumour tissue DNA. (B) DNA sequencing of
the corresponding normal tissue DNA. (C) DNA sequencing of the tumour DNA revealed a
T → C substitution at the position 802 − 29 in intron 7 (indicated by an arrow).
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Results
Only one of the 33 oesophageal squamous cell
carcinoma samples showed an aberrant SSCP
shift in exon 8. Further DNA sequencing analy-
sis of this sample revealed an 802 − 29 T → C
substitution in intron 7 (fig 1). No PTEN/
MMAC1 mutations were found in the muta-
tional “hot spot” in exon 5 by means of direct
sequencing of six tumour samples and three
corresponding morphologically normal tissues
with a normal SSCP migration pattern. How-
ever, a deletion of one nucleotide T at the posi-
tion 492 +8 in intron 5 was seen in all samples,
including tumours and the corresponding mor-
phologically normal tissues (fig 2).
Discussion
Our study is the first report of mutational
analysis of the recently discovered PTEN/
MMAC1 tumour suppressor gene in primary
oesophageal squamous cell carcinomas. We
detected only one mutation in intron 7 among
the nine exons of the PTEN/MMAC1 gene in
33 primary oesophageal squamous cell carci-
noma samples. PCR–SSCP analysis is a
method with high sensitivity and is the most
widely used method for detecting gene muta-
tions. Thus, the relative absence of mutations
in the PTEN/MMAC1 coding region in the 33
primary oesophageal squamous cell carcinoma
samples analysed in our study strongly indi-
cated that PTEN/MMAC1 gene mutation is an
extremely rare event in oesophageal carcino-
genesis. Nevertheless, other mechanisms of
inactivation of the PTEN/MMAC1 gene, such
as homozygous deletion, hypermethylation, or
protein phosphorylation, have still to be inves-
tigated. However, they are not known to be
important mechanisms for PTEN/MMAC1
inactivation in other tumours.
Analysis of the PTEN/MMAC1 gene in
squamous cell carcinomas from other sites also
found that PTEN/MMAC1 gene mutation
does not contribute greatly to the formation of
squamous cell carcinoma of lung,10 cervix,17
skin,18 or head and neck.9 19 Petersen et al failed
to detect any mutation in the PTEN/MMAC1
gene in 25 lung squamous cell carcinomas.10
Tashiro et al did not find any mutation of
PTEN/MMAC1 in 10 cervical squamous
carcinomas.17 Okami and colleagues9 described
only four mutations of PTEN/MMAC1 in 39
primary head and neck squamous cell carcino-
mas, and Henderson and colleagues19 did not
find any mutations of PTEN/MMAC1 in 10
head and neck squamous cell carcinoma cell
lines and biopsy tumour samples. In addition,
Kubo et al did not detect any mutations of
PTEN/MMAC1 in 21 skin squamous cell
carcinomas.18 These observations of a lack of
PTEN/MMAC1 mutation in squamous cell
carcinoma from other sites are in concurrence
with our observations from oesophageal
squamous cell carcinoma. These findings indi-
cate that the mutation of the PTEN/MMAC1
gene is a rare event in the carcinogenesis of
squamous cell carcinoma.
PTEN/MMAC1 mutations were frequently
found in cancers arising from endo-
metrium,8 17 20 brain,1 2 16 21–24 and prostate.25–27
As cited above, they are rarely seen in carcino-
mas arising from the head and neck region
(including oesophagus),9 19 lung,10 cervix,17 and
skin,18 or in adenocarcinomas arising from
colorectum,8 pancreas,8 9 28 ovary,11 17 28 and
kidney.28 These findings suggest that the tumori-
genic eVects of the PTEN/MMAC1 gene are
tissue specific. In other words, the PTEN/
MMAC1 gene plays a role in the tumorigenesis
of some cancers but not in others.
In our study, we found a mutation in intron
7 in one of 33 oesophageal squamous cell car-
cinomas. The corresponding morphologically
normal tissue did not show this abnormality.
The importance of this mutation is unclear, but
it is unlikely that this mutation plays a major
role in the carcinogenesis of oesophageal
squamous cell carcinoma. This is because this
mutation is not in the coding region of PTEN/
MMAC1 and is 29 base pairs away from the
exon–intron junction. However, whether this
Figure 2 DNA sequence analysis of PTEN/MMAC1 gene exon 5 (GenBank accession
number, AF000730). Alignment of sequences from corresponding normal tissue and tumour
tissue showing a deletion of one nucleotide T at position 492 +8 in intron 5 in both normal
and tumour tissues (small letters represent intron 5).
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mutation in the intron aVects transcriptional or
post-transcriptional modulation remains to be
elucidated.
Most reports of mutations found in PTEN/
MMAC1 are localised to exon 5,6 16 22 24 the
sequence encoding the putative phosphatase
domain.Thus, we randomly chose six oesopha-
geal squamous cell carcinoma samples and the
three corresponding morphologically normal
tissues with normal SSCP patterns to sequence
the hot spot exon 5 and its flanking regions.
Although we could not find a cancer linked
abnormality in exon 5, we detected a mutation
in intron 5 in both tumours and corresponding
morphologically normal tissues. Because all the
six tumours and three corresponding normal
tissues had a deletion of one nucleotide T at
position 492 +8 in intron 5, it is unlikely that
this is a germline mutation. The importance of
this deletion in intron 5 remains unclear. It is
possible that this might be the result of allelic
variation of the PTEN/MMAC1 gene in diVer-
ent ethnic groups.
The exact molecular mechanism(s) by which
PTEN/MMAC1 functions in tumorigenesis or
growth inhibition remains unclear. Based on the
sequence homologies of the PTEN/MMAC1
protein and protein tyrosine phosphatases, the
PTEN/MMAC1 protein was defined as a dual
specificity phosphatase with a high degree of
substrate specificity.4 More recent studies
showed that the PTEN/MMAC1 protein de-
phosphorylates the 3 position of phosphatidyli-
nositol 3,4,5-trisphosphate to reverse the reac-
tions catalysed by phosphoinositide 3-kinase.29–31
This indicates that PTEN/MMAC1 inhibits the
phosphoinositide 3-kinase signalling pathway
for regulation of cell growth and survival.
Furthermore, Davies et al showed that the
PTEN/MMAC1 protein inhibits Akt activation
and induces anoikis, a kind of apoptosis.32 This
implies that loss of PTEN/MMAC1 increases
cellular proliferation and augments a cell’s
survival potential during cellular processes that
are associated with malignant transformation. In
addition, Tamura et al suggested that the
PTEN/MMAC1 protein disrupts cell spreading
and migration by dephosphorylating focal adhe-
sion kinase.33 Thus, mutation of PTEN/
MMAC1 will enhance tumour spreading.
In conclusion, our results suggest that
PTEN/MMAC1 gene mutations do not play
an important role in the carcinogenesis of
oesophageal squamous cell carcinoma.
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